Table 1.
Baseline Characteristics of Study Participants.
| Breakthrough Infection (n = 8) |
Non-Breakthrough Infection (n = 288) |
All (n = 296) | |||
|---|---|---|---|---|---|
| Baseline PCR Negative (n = 5) |
Baseline PCR Positive (n = 3) |
Baseline PCR Negative (n = 245) |
Baseline PCR Positive (n = 43) |
||
| Female | 2 (40%) | 1 (33%) | 201 (82%) | 33 (75%) | 237 (80%) |
| Age (years) | 38.4 ± 10.7 | 35.3 ± 6.1 | 44.2 ± 12.3 | 41.9 ± 11.9 | 43.7 ± 12.2 |
| Ethnicity | |||||
| African American | 5 (2%) | 5 (2%) | |||
| Asian | 16 (7%) | 1 (2%) | 17 (6%) | ||
| Caucasian | 5 (100%) | 3 (100%) | 203 (83%) | 37 (86%) | 248 (83%) |
| Hispanic | 15 (6%) | 5 (11%) | 20 (7%) | ||
| Vaccine Product | |||||
| mRNA-1273 | 3 (60%) | 3 (100%) | 105 (43%) | 26 (60%) | 137 (46%) |
| bnt162b2 | 2 (40%) | 140 (57%) | 17 (40%) | 159 (54%) | |
| Heart Disease | 4 (2%) | 1 (2%) | 5 (2%) | ||
| Lung Disease | 2 (1%) | 2 (1%) | |||
| Diabetes | 5 (2%) | 5 (2%) | |||
| Obesity | 9 (4%) | 9 (3%) | |||
| Lifetime Smoking or Vaping history | 9 (4%) | 2 (5%) | 11 (4%) | ||
| Pregnancy | 1 (0%) | 1 (0%) | |||
| Moderate or Severe Immunocompromise | 8 (3%) | 8 (3%) | |||